Amici Clinical Research has signed a long-term lease for 6,402 square feet at the Class A office property at 10 Independence Blvd. in Warren, JLL announced Monday.
The addition of Amici, which took custom space on the property’s first floor, means the 120,528-square-foot center is nearing full occupancy.
JLL represented the building’s ownership, American Equity Partners, in the transaction.
Amici, a division of the IMA Group’s network of integrated research sites specializing in clinical trials in multiple therapeutic areas, is relocating from 34 E. Somerset St. in Raritan. It will take occupancy of its new space next month.
JLL Managing Director Bob Ryan and associate T.J. Romano serve as exclusive leasing agents. Larry Dickstein, CEO of Dickstein Real Estate Services, represented the tenant.
“We are delighted to announce this new lease that brings 10 Independence Blvd. to 92% occupancy and solidifies the property’s position as a leading corporate location in prestigious Warren Township,” Ryan said.
“The building’s consistent appeal to premier corporate occupiers is a testament to American Equity Partners’ repositioning effort and its commitment to meet the needs of tenants seeking exceptional work environments and best-in-class amenities.”
The four-story property at 10 Independence Blvd. was built in 1988 and meticulously renovated by American Equity Partners to meet the demands of corporate occupiers seeking superior quality space. Ownership redesigned the building’s two-story atrium as a bright and welcoming modern entrance, and upgraded common areas, restrooms and elevator cabs.
New amenities include a common conference space, expansive tenant lounge with game room and a comprehensive fitness center, while EV charging stations have been installed within the 410-car exterior surface parking lot.
Major tenants include pharmaceutical company Cipla USA Inc., Envision Pharma and wireless giant T-Mobile. AEP is also constructing a new retail building at the site that will be anchored by Dunkin Donuts and is scheduled for completion in the second quarter of 2023.
Ownership has completed a custom buildout for Amici, creating an efficient and highly collaborative space that will enable the company to conduct its work with participants in clinical trials for vaccines and new therapies. Amici has expertise in fatty liver, cardiovascular, pulmonary and neurologic diseases as well as endocrinology, dermatology and vaccine studies, among the fastest-growing categories of clinical research today.
